pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

40 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 213 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase 1 initiation×clear all
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa213
  • phase 2 completion172
  • phase 1 completion73
phase 2 initiation
62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Oncology13
    • Dermatology5
    • Immunology5
    • Cardiology4
    • Infectious Disease4

    Week of Apr 20, 2026

    1
    ›Apr 24, 2026phase 1 initiation90d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

    Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

    full page →CMSD-001 →source: globaldata

    Week of Apr 27, 2026

    39
    ›Apr 27, 2026phase 1 initiation87d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

    full page →pembrolizumab →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

    Therapy area: Immunology. Indication: Liver Transplant Rejection

    full page →fostamatinib →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoCity of Hope — CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] (Phase I Trial Initiation)CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]

    Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas

    full page →CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoNational Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Autologous B7-H3 CAR T

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor

    full page →Autologous B7-H3 CAR T →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoHelixon — HXN-6005 (Phase I Trial Initiation)HXN-6005

    Therapy area: Undisclosed. Indication: Unspecified

    full page →HXN-6005 →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase I Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 1 initiation87d agoArdi Farma Ilac Pazarlama Tic Ltd — clozapine (Phase I Trial Initiation)clozapine

    Therapy area: Central Nervous System. Indication: Schizophrenia, Unspecified Neurologic Disorders

    full page →clozapine →source: globaldata
    ›Apr 28, 2026phase 1 initiation86d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

    Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

    full page →BW-20805 →source: globaldata
    ›Apr 28, 2026phase 1 initiation86d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

    Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

    full page →HN-2302 →source: globaldata
    ›Apr 28, 2026phase 1 initiation86d agoBio-Innova Co Ltd — febuxostat (Phase I Trial Initiation)febuxostat

    Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Gouty Arthritis (Gout), Hyperuricemia

    full page →febuxostat →source: globaldata
    ›Apr 28, 2026phase 1 initiation86d agoVirginia Commonwealth University — fluorouracil (Phase I Trial Initiation)Efudex

    Therapy area: Dermatology. Indication: Burns

    full page →Efudex →source: globaldata
    ›Apr 28, 2026phase 1 initiation86d agoNovo Nordisk AS — cagrilintide hydrochloride (Phase I Trial Initiation)cagrilintide hydrochloride

    Therapy area: Metabolic Disorders. Indication: Obesity, Overweight

    full page →cagrilintide hydrochloride →source: globaldata
    ›Apr 28, 2026phase 1 initiation86d agoOvid Therapeutics Inc — OV-4071 (Phase I Trial Initiation)OV-4071

    Therapy area: Central Nervous System. Indication: Parkinson's Disease

    full page →OV-4071 →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoAgios Pharmaceuticals Inc — AG-181 (Phase I Trial Initiation)AG-181

    Therapy area: Metabolic Disorders. Indication: Phenylketonuria (PKU)

    full page →AG-181 →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoLuye Pharma Group Ltd — LY-03015 (Phase I Trial Initiation)LY-03015

    Therapy area: Central Nervous System. Indication: Huntington Disease, Tardive Dyskinesia

    full page →LY-03015 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoEgyptian International Pharmaceuticals Industries Co SAE — enoxaparin sodium biosimilar (Phase I Trial Initiation)enoxaparin sodium biosimilar

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Congestive Heart Failure (Heart Failure), Deep Vein Thrombosis (DVT), Myocardial Infarction, Pulmonary Embolism, Thromboembolic Disease, Thromboembolism, Thrombosis, Unstable Angina, Venous (Vein) Thrombosis, Venous Thromboembolism

    full page →enoxaparin sodium biosimilar →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoQilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)QLS-5212

    Therapy area: Oncology. Indication: Solid Tumor

    full page →QLS-5212 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

    full page →Loberamisal →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoVanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)nivolumab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Oral Cavity (Mouth) Cancer, Squamous Cell Carcinoma

    full page →nivolumab →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

    Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

    full page →GS-1701 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

    Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

    full page →VC-005 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoChiral Biotech Pharma Pty Ltd — esketamine hydrochloride (Phase I Trial Initiation)esketamine hydrochloride

    Therapy area: Central Nervous System. Indication: Treatment Resistant Depression

    full page →esketamine hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

    Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

    full page →MK-6050 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoGan & Lee Pharmaceuticals Co Ltd — GLR-2037 (Phase I Trial Initiation)GLR-2037

    Therapy area: Oncology. Indication: Prostate Cancer

    full page →GLR-2037 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoBeijing Continent Pharmaceutical Co Ltd — F-351 (Phase I Trial Initiation)F-351

    Therapy area: Gastrointestinal. Indication: Liver Fibrosis

    full page →F-351 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

    Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

    full page →DAPAGLIFLOZIN →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoAvance Clinical Pty Ltd — ZE-740282 (Phase I Trial Initiation)ZE-740282

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myeloproliferative Disorders, Polycythemia Vera

    full page →ZE-740282 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoByterna Therapeutics Ltd — BR-101 (Phase I Trial Initiation)BR-101

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →BR-101 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoBristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)navlimetostat

    Therapy area: Oncology. Indication: Biliary Tumor, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

    full page →navlimetostat →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoShanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)HLX-3901

    Therapy area: Oncology. Indication: Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →HLX-3901 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoCentre Hospitalier Universitaire de Nice — Leucogenase (Phase I Trial Initiation)Leucogenase

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

    full page →Leucogenase →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoJiangsu Hansoh Pharmaceutical Group Co Ltd — HS-10506 (Phase I Trial Initiation)HS-10506

    Therapy area: Central Nervous System. Indication: Depression, Insomnia

    full page →HS-10506 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoKexing Biopharm Co Ltd — GB-18 (Phase I Trial Initiation)GB-18

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cachexia, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor, Unspecified Cancer

    full page →GB-18 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoBeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)BGC-0979

    Therapy area: Oncology. Indication: Solid Tumor

    full page →BGC-0979 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

    Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

    full page →IASO-782 →source: globaldata
    ›Apr 30, 2026phase 1 initiation84d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →DASATINIB →source: globaldata
    $AGIO36.52-2.26%
    $OCGN1.3000-2.26%
    $GILD132.14+1.43%
    $OVID2.3500-2.49%
    $ONC318.69+2.61%
    $MRK126.26+1.50%